What is new and conclusion: Given the heterogeneity of the data, a preferred regimen has not emerged. Prescribers must take into consideration recent exposure, source control, and available synergy and clinical data. Further comparative trials are needed to establish a preferred regimen and the creation of a universal treatment algorithm.
| WHAT IS K NOWN AND OBJEC TIVE
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia represents a major burden on health care, with early studies demonstrating mortality rates as high as 60% and associated with a 2-fold increase in mortality compared to methicillin-susceptible S. aureus (MSSA) bacteraemia (OR, 1.93; 95% CI, 1.54-2.42; P < 0.001).
1,2 The Center for Disease Control and Prevention (CDC) classifies MRSA as a severe threat in health care, leading to 80 000 invasive infections and resulting in over 11 000 deaths each year. 3 Despite the difficulties in treating invasive MRSA infections, randomized controlled trials continue to target noninferiority for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), with little emphasis on treatment of more invasive infections.
Treatment of MRSA bacteraemia is directed by the Infectious
Diseases Society of America (IDSA) MRSA guidelines which recommend either vancomycin or daptomycin as first-line agents. 4 Neither agent is without limitations. The most apparent concern with vancomycin is trough-and duration-dependent nephrotoxicity. 5 Concerns have also risen regarding slow bacterial killing, minimum inhibitory concentration (MIC) "creep," variable tissue penetration and the emergence of intermediate and resistant strains. 4 Daptomycin cannot be used for lower respiratory tract pneumonia and has been associated with rhabdomyolysis and eosinophilic pneumonitis. 4 Of note, prior treatment with vancomycin is associated with more rapid emergence of daptomycin nonsusceptible (DNS) strains, resulting in cell wall thickening that essentially hinders daptomycin from reaching the cytoplasmic membrane.
6
The current IDSA definition of persistent MRSA bacteraemia is suggestive of blood cultures past 7 days of adequate therapy at effective doses. 4 However, blood sterility is highly dependent on source control and the removal of infectious foci. 4 As such, an absolute or objective definition is difficult to provide due to the complexity and variability of MRSA manifestations. Ultimately, clinical judgement is paramount when identifying persistent B and treatment failure. Independent risk factors for persistent MRSA bacteraemia include endocarditis, septic shock, complicated bacteraemia, decreased vancomycin susceptibility, vancomycin heteroresistance, agr dysfunction, low-level in vitro resistance to thrombin-induced platelet microbicidal protein. [7] [8] [9] Another study demonstrated that metastatic infection, congestive heart failure and increasing vancomycin MICs were independent predictors of 30-day mortality in persistent MRSA bacteraemia. (TMP-SMX) or a β-lactam antibiotic. 4 There are no recommended salvage combinations with vancomycin. Furthermore, although combination β-lactam therapy is mentioned, the IDSA MRSA guidelines do not specify a preferred β-lactam. Given the lack of head-to-head studies, no single agent or regimen has emerged as the preferred treatment for persistent MRSA bacteraemia.
Ultimately, development of a salvage regimen should take into consideration resistance testing, source tissue penetration, recent antibiotic exposure and available evidence. This review will focus on compiling the evidence that exists for the treatment of persistent MRSA bacteraemia.
| ME THODS
The data included in the review were identified by searches of 
| RE SULTS

| Daptomycin-based regimens
Current evidence supports that the FDA-approved doses of daptomycin, in particular when used in the setting of vancomycin failure or in deep-seated infections, may result in daptomycin nonsusceptibility. 11, 12 Both the IDSA and the European Society of Cardiology recommend higher doses of daptomycin for endovascular infections as well as for persistent MRSA bacteraemia secondary to the drug's concentration-dependent killing. 4, 13 The safety and efficacy of highdose daptomycin (up to 12 mg/kg) are well described. [14] [15] [16] [17] [18] This section will focus on combination therapy. For a summary of available evidence, see Table 1 . 
| Daptomycin plus antistaphylococcal β-lactams
| Daptomycin plus trimethoprimsulfamethoxazole
Daptomycin plus TMP-SMX has also garnered attention as a thera- 
| Daptomycin plus rifampin
The utility of daptomycin plus rifampin in prosthetic device infections has been previously described in animal models and retrospective reviews. [29] [30] [31] [32] [33] This combination highlights rifampin's potent ability to penetrate biofilm and exert bactericidal activity independ- killing significantly sooner than daptomycin plus rifampin or linezolid plus rifampin, P = 0.02 and 0.05, respectively). 36 In the absence of further data, clinical utility of this regimen remains unknown at this time. 
| Daptomycin plus fosfomycin
| Vancomycin-based regimens
Vancomycin has historically been the workhorse for invasive MRSA infections; thus, it is often the agent implicated in treatment failure. Treatment strategies for persistent MRSA bacteraemia typically involve transitioning from vancomycin to another regimen. On occasion, vancomycin-based salvage therapy is attempted with another agent with appropriate source tissue penetration and/or in vitro synergy. A summary of the in vivo evidence is shown in see Table 2 .
| Vancomycin plus antistaphylococcal β-lactams
In vitro studies have demonstrated synergistic interactions between vancomycin and a wide variety of β-lactams against S. aureus.
43,44
The proposed mechanism for vancomycin and β-lactam synergy is related to cell wall thinning via the addition of a β-lactam, which increases vancomycin binding to target sites during cell wall synthesis. 45 The degree of synergy demonstrated between vancomycin and β-lactams appears to correlate with increasing vancomycin MIC.
44,46
The combination of vancomycin plus nafcillin has been shown to be successful in two rabbit models of IE, with one model demonstrating sterilization of the bloodstream within 24 hours in 92% of the animals infected with VRSA. of vancomycin/β-lactam combination versus standard monotherapy for MRSA bacteraemia. 
| Vancomycin plus ceftaroline
The combination of vancomycin and ceftaroline is unique in that there is the advantage of ceftaroline's independent activity against MRSA combined with its β-lactam synergistic potential. Beyond in vitro data demonstrating potent synergy, a recent case series has presented moderate therapeutic success with the combination of ceftaroline and vancomycin. 43 The case series included five patients with vancomycin-refractory MRSA bacteraemia secondary to endocarditis (n = 2), epidural abscess (n = 2) and iliopsoas abscess (n = 1) who received vancomycin plus ceftaroline with four of the five patients experiencing a microbiological cure and one patient transitioned to palliative care. 53 
| Vancomycin-sparing and daptomycinsparing regimens
| Ceftaroline
In conjunction with in vitro data, the reliable activity against MRSA makes ceftaroline a viable option as a part of most salvage regimens for deep-seated infections such as endocarditis or where previous exposure to vancomycin or daptomycin failed to result in bloodstream sterilization. 56 As previously mentioned, combination therapy with either vancomycin or daptomycin has been described; however, ceftaroline monotherapy has also been used as salvage (available in vivo evidence shown in Table 3 ). At present, no randomized clinical trials have been conducted using ceftaroline for persistent MRSA bacteraemia, and thus, the available data are limited to cases reports and case series. One of the first reports documenting successful clearance of persistent MRSA bacteraemia was a case series from Ho et al. 57 Notable from this publication was the every 8-hour dosing strategy employed resulting in effective bacterial eradication from the bloodstream. In vitro data corroborate an every 8-hour dosing strategy which optimizes the pharmacokinetic/pharmacodynamics of ceftaroline; however, additional clinical experience with standard and high-dose has also been associated with clinical success.
56,58-63
A case series reported success with ceftaroline plus TMP-SMX for salvage therapy in 26/29 patients. Median duration of bacteraemia was 9.5 days before switching to ceftaroline plus TMP-SMX, resulting in a median time to blood sterilization of 1.5 days. Noted overall success was 31%; however, the study defined success as no clinical or microbiological recurrence at least 6 weeks after completion. 64 Ceftaroline plus TMP-SMX appears to be a promising option, particularly in deep-seated infections when daptomycin-or vancomycin-based regimens are not an option.
| Linezolid
Although linezolid is bacteriostatic often limiting its use in bacteraemia, data for use as a salvage option in persistent MRSA bacteraemia are plentiful. [65] [66] [67] The most well-known study was conducted by 
| Telavancin
Animal infection models of Staphylococcal bacteraemia with telavancin displayed overwhelmingly positive results when compared to vancomycin. Moreover, data from these studies demonstrated lower mortality compared to vancomycin controls. [71] [72] [73] In vivo data using telavancin for MRSA bacteraemia are limited to the Phase 2 ASSURE study and a subpopulation of the ATTAIN study. 74 In the ASSURE study, patients in the clinically evaluable arm had similar cure rates when compared to standard of care; however, the number of patients in each arm was small. In the ATTAIN trial, those patients with bacteraemic hospital-acquired pneumonia were compared with telavancin demonstrating a higher cure rate numerically, although further exploration is warranted. 74 A case series of 14 patients with persistent MRSA bacteraemia failing vancomycin or daptomycin were treated with telavancin • ME: 71% (5/7)
• TE (median): NR AV, arteriovenous; CPT, ceftaroline; CS, clinical success; DAP, daptomycin; FOS, fosfomycin; GNT, gentamicin; IE, infective endocarditis; IMI, imipenem; LZD, linezolid; MRSA(-B), methicillin-resistant Staphylococcus aureus (bacteraemia); ME, microbiologic eradication; NR, not reported; QP-DP, quinupristin-dalfopristin; RIF, rifampin; TE, time to eradication; TMP-SMX, trimethoprim-sulfamethoxazole; TEL, telavancin; VAN, vancomycin. resulting in a 57% (8/14) success rate with 62% (9/14) of patients experiencing culture clearance within 48 hours. 75 Another case series with eight patients undergoing haemodialysis with persistent MRSA bacteraemia failing vancomycin or daptomycin were switched to telavancin 10 mg/kg thrice weekly or every other day.
Microbiological clinical cure was achieved in 7/8 (87.5%) with a median duration of bacteraemia of 1 day (range 0-11 days). 76 It
should be noted that telavancin demonstrated higher rates of nephrotoxicity and increased rates of mortality in patients with reduced renal function compared to vancomycin, leading to a boxed warning for nephrotoxicity and for use in patients with CrCl <50 mL/min. 77 Lower doses (7.5 mg/kg daily) appear to be equal in efficacy in vitro to the FDA-approved dose of 10 mg/kg daily. 78 Further research is needed to determine whether the lower dose has a role in the treatment of persistent MRSA bacteraemia or is associated with less nephrotoxicity. Outside of patients with reduced renal function, telavancin may be a potential option for salvage therapy.
| Fosfomycin
Intravenous fosfomycin is not yet available in the United States.
However, clinical experience with fosfomycin in cases of persistent MRSA bacteraemia is promising with the FOSIMI study being the most well described. 79 With known synergy between fosfo- The authors concluded QP-DP may be a reasonable choice as rescue therapy in critically ill patients failing vancomycin. However, drug toxicity has ultimately rendered QP-DP as a last-line salvage option.
| Combinations unlikely to be beneficial
In vitro data assessing the combinations with linezolid and daptomycin and vancomycin have shown mixed results with some studies observing antagonism whereas others showing indifference.
84-87
Smith et al 88 93 The relationship between reduced vancomycin susceptibility and daptomycin nonsusceptibility further limits any foreseeable benefit. 94 At this time, vancomycin plus daptomycin combinations cannot be recommended.
Although gentamicin and rifampin remain the standard of care for staphylococcal prosthetic valve endocarditis, routine use outside of prosthetic device infections is not recommended. The ARREST trial, a large, multicentre, randomized, double-blind, placebo-controlled trial, compared the addition of rifampin or placebo to standard therapy for the treatment of S. aureus bacteraemia, resulted in no difference in rates of treatment failure, recurrence or mortality (17% vs 18%, respectively, P = 0.81). However, the rifampin arm compared to placebo showed higher rates of adverse reactions (17% vs 10%, respectively, P = 0.004) and drug interactions (6% vs 2%, respectively, P = 0.005). 95 Gentamicin is no longer recommended for IE due to high rates of intrinsic gentamicin resistance, a lack of proven efficacy and toxicity issues. 96 Cosgrove et al 97 
| Duration of therapy
Although the exact duration of treatment for persistent MRSA bacteraemia may be difficult to define, treatment courses are often extensive. Per the IDSA MRSA guidelines, persistence of bacteraemia after 2-4 days is one of the criteria for complicated bacteraemia and thereby necessitating at least 4-6 weeks of treatment. 4 Longer durations may be required depending on the length of time required to demonstrate blood sterility. Endocarditis and osteomyelitis often require treatments of at least 6 weeks. 96 In the studies evaluating combination therapy, most continued both agents for the entire duration begging the question whether this is truly necessary. Barber et al evaluated the possibility of therapeutic de-escalation in an in vitro hollow fibre model. After 96 hours of daptomycin plus ceftaroline combination, therapy was either continued, discontinued or changed to either agent monotherapy. 98 Only the isolates that had therapy discontinued demonstrated significant regrowth, supporting the possibility of de-escalation to a single agent after 4 days.
Further research is needed as this study only tested one combination against two clinical MRSA isolates. Therapy for S. aureus infections is often changed from vancomycin to another agent; however, in vitro data suggest a diminished response to isolates previously exposed to vancomycin. 99 Future research is needed to determine the cause and effect of vancomycin failure and the impact on subsequent agents. Prospective, randomized, controlled trials of patients failing initial therapy will be challenging to conduct, given the difficulties with patient enrolment, multiple confounders associated with source control, and ambiguities regarding the definition of treatment failure. The majority of evidence for treatment options is likely to continue to come from case reports, case series and retrospective cohort studies.
| WHAT IS NE W AND CON CLUS I ON
Although a universal algorithm is likely not feasible based on heterogeneity of available data, a complete regimen change seems in order rather than adding another agent to a failing regimen.
Daptomycin-or ceftaroline-based regimens have the most robust data for the treatment of persistent MRSA bacteraemia. 
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